Thermo Fisher Scientific to Participate in Capitol Hill Briefing on Precision Medicine Advancements

CARLSBAD, Calif., Sept. 27, 2017 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it will participate in a Capitol Hill briefing hosted by AdvaMedDx and LUNGevity Foundation to discuss leading developments in medical diagnostics that are shaping the way patients are tested and treated for disease in the era of molecular-based medicine. The briefing, titled the Importance of Advanced Diagnostics in the Precision Medicine Paradigm, is scheduled at noon in the Rayburn House Office Building 2044, Washington, DC, on October 16.

"As we've seen from the landmark FDA approvals this year, the testing and treatment paradigm for diseases like cancer are rapidly moving toward one that places greater emphasis on identifying the genetic drivers of disease to help physicians select the right treatment for their patients," said Joydeep Goswami, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific. "Educating key stakeholders of these developments, including our country's lawmakers and the public they serve, is a vital mission to ensure those in need can benefit from them."

The briefing will bring together a panel of speakers to share background on the tremendous progress that has been made in the last few years in the areas of advanced diagnostics and precision medicine, as well as discuss key issues that support innovation and access in these areas, including quality and reimbursement.

"We are pleased to have Joydeep Goswami from Thermo Fisher serve on our panel of distinguished speakers for this briefing," said Andrew Fish, Executive Director, AdvaMedDx and Chief Strategy Officer, AdvaMed. "AdvaMedDx member companies are on the forefront of precision medicine as diagnostic tests are a cornerstone of cancer treatment and care. We look forward to continuing to educate policymakers on their value to the health care system in the hopes that together, we can address barriers to implementation and make sure that patients have access to these new therapies."

Thermo Fisher recently received U.S. Food and Drug Administration approval in June for its Oncomine Dx Target Test, the first next-generation sequencing (NGS)-based diagnostic that simultaneously evaluates 23 genes clinically associated with non-small cell lung cancer (NSCLC). It also serves as a companion diagnostic (CDx) for three FDA-approved therapies for NSCLC. The test expedites the process of evaluating patient tumor samples, enabling physicians to match patients to the therapies in days instead of weeks.

Thermo Fisher is scheduled to participate in several precision medicine-focused presentations at upcoming industry conferences, including:

    --  Sept. 29: "Gene Panels and Precision Oncology - A Look at How Targeted
        Next-Generation Sequencing is Shaping Better Outcomes for Cancer
        Patients." Cancer Therapeutics and Partnering Summit in San Diego.
    --  Oct. 7:  "The Future of Genomic Testing" College of American
        Pathologists (CAP) annual conference, Washington DC.
    --  Oct. 16: "Mutational testing in lung cancer," IASLC 18(th) World
        Conference on Lung Cancer, Yokohama, Japan.
    --  Oct. 19: "Advancing Precision Medicine with NGS Companion Diagnostics -
        Successes, challenges, and future opportunities," World CDx, Boston.
    --  Nov. 15: "Identifying the Right Patient for the Right Therapy Using a
        Universal Companion Diagnostic Test," 13(th) annual Personalized
        Medicine Conference, Boston.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands - Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services - we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

    Media Contact Information:

    Mauricio Minotta                   Maurissa Messier

    Thermo Fisher Scientific           CG Life

    +1 760 929 2456                                       +1 908 208 9254

    +1 760 805-5266 (mobile)          mmessier@cglife.com

    Mauricio.minotta@thermofisher.com

View original content:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-participate-in-capitol-hill-briefing-on-precision-medicine-advancements-300525445.html

SOURCE Thermo Fisher Scientific